CClinicalTrials.gg
CompletedNCT01425047Updated Sep 2, 2011

Bioavailability of Xanthones From Mangosteen

An observational study in Healthy Volunteers, sponsored by Mark Failla. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-02.

Sponsored by Mark Failla · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Mangosteen is a tropical tree. The peel of mangosteen fruit is used in traditional medicine. The purpose of this study was to determine the bioavailability of the xanthones from mangosteen juice in adult human subjects.

Read the detailed description

Garcinia mangostana L. (mangosteen) is a tropical tree native to Southeast Asia. The pericarp of mangosteen fruit is used in traditional medicine to treat inflammation, infections, wounds, and diarrhea. The proposed health-promoting effects have been attributed to a family of polyphenols referred to as xanthones. Since its introduction into the United States, juices and products containing mangosteen fruit have become a top-selling botanical dietary supplement. This commercial success largely has been the result of aggressive marketing of health claims based on in vitro observations and anecdotal reports.

The purpose of this study was to determine the bioavailability of xanthones from mangosteen juice in adult human subjects. After an overnight fast of at least 10h, male and female subjects were admitted to the Ohio State University Clinical Research Center. Volunteers ingested 2 ounces of 100% mangosteen juice as part of a western-style breakfast. Pericarp particles accounted for 1% of the mass and 99% of total xanthone content in the juice. This dose provided 130 ± 2 mg total xanthones. Blood was collected prior to breakfast and 1,2,3,4,6,8 and 24h. Subjects were fed a mangosteen-free lunch and released from the unit after the 8h collection, refraining from mangosteen containing products until final collection of blood at 24h. Urine was collected for the 24 test period.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • mangosteen
  • xanthones
  • dietary supplement
  • botanical supplement
  • bioavailability
  • Determine bioavailability of mangosteen xanthones in adults
03

In context

Lead sponsor

This is the only study on the registry with Mark Failla as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

5 female and 5 male healthy, non-smoking subjects admitted to the Clinical Research Center at The Ohio State University.

Inclusion criteria

  • 5 female
  • 5 male
  • body mass index \</= 30
  • normal renal function
  • non-smoking

Exclusion criteria

Exclusion Criteria:

  • smokers
  • acute or chronic diseases
  • history of gastrointestinal diseases
  • >/= 10% weight loss
  • dietary or herbal supplement within 6 months of study
  • pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Females ingesting mangosteen juice
  • Males ingesting mangosteen juice
06

What researchers measure

Primary outcomes

  1. Xanthones in urine

    Urine was collected prior to ingesting mangosteen juice with breakfast and then from consumpotion of juice until 24h.

    Time frame: 0-24 hours

Secondary outcomes

  1. Xanthones in sera

    Blood was collected prior to breakfast, and 1, 2, 3, 4, 6, 8 and 24 hours

    Time frame: 0-24 hours

07

Study locations

1 site
  • The Ohio State University, Clinical Research Center
    Columbus, Ohio 43210, United States
08

References and documents

Publications

  • Chitchumroonchokchai C, Riedl KM, Suksumrarn S, Clinton SK, Kinghorn AD, Failla ML. Xanthones in mangosteen juice are absorbed and partially conjugated by healthy adults. J Nutr. 2012 Apr;142(4):675-80. doi: 10.3945/jn.111.156992. Epub 2012 Mar 7. PubMed 22399525 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01425047
Lead sponsor
Mark Failla
Collaborators
Ohio State University
Responsible party
Mark Failla (Professor, Human Nutrition, Associate Dean for Research, Ohio State University) — Sponsor-investigator
First posted
Aug 29, 2011
Start date
Nov 2010
Primary completion
Nov 2010
Completion
Feb 2011
Last update
Sep 2, 2011

Study contacts

Mark Failla, PhD
principal investigator · Ohio State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion